1
, 2
Essentials of Clinical Radiation
Oncology –Test Bank
Third Edition
Chapter List
1. Glioblastoma, IDH-Wildtype 20. Cutaneous Squamous Cell
2. IDH-Mutant Gliomas: Grade 3 Carcinoma and Basal Cell Carcinoma
3. Low Grade Gliomas 21. Merkel Cell Carcinoma
4. Meningioma 22. Malignant Cutaneous Melanoma
5. Primary Central Nervous System 23. Mycosis Fungoides
Lymphoma 24. Early-Stage Breast Cancer
6. Pituitary Neuroendocrine Tumor 25. Locally Advanced Breast Cancer
7. Trigeminal Neuralgia 26. Ductal Carcinoma In Situ
8. Vestibular Schwannoma 27. Recurrent Breast Cancer
9. Uveal Melanoma 28. Early-Stage Non–Small-Cell Lung
10. Spine Tumors Cancer
11. Oropharynx Cancer 29. Stage III Non–Small-Cell Lung
Cancer
12. Oral Cavity Cancer
30. Small-Cell Lung Cancer
13. Nasopharyngeal Cancer
31. Mesothelioma
14. Laryngeal Cancer
32. Thymoma
15. Salivary Gland Tumors
33. Esophageal Cancer
16. Carcinoma of Unknown Primary of
the Head and Neck 34. Gastric Cancer
17. Postoperative Radiation for Head 35. Hepatocellular Carcinoma
and Neck Cancer 36. Pancreatic Adenocarcinoma
18. Thyroid Cancer 37. Rectal Cancer
19. Sinonasal Tumors 38. Anal Cancer
39. Cholangiocarcinoma
, 2
40. Low-Risk Prostate Cancer 56. Leukemia
41. Intermediate- and High-Risk 57. Soft Tissue Sarcoma
Prostate Cancer 58. Medulloblastoma
42. Post-Prostatectomy Radiation 59. Ependymoma
Therapy
60. Brainstem Glioma
43. Bladder Cancer
61. Craniopharyngioma
44. Testicular Cancer
62. Rhabdomyosarcoma
45. Penile Cancer
63. Neuroblastoma
46. Urethral Cancer
64. Wilms Tumor
47. Renal Cell Carcinoma
65. Ewing Sarcoma
48. Cervical Cancer
66. Pediatric Hodgkin Lymphoma
49. Uterine Cancer: Endometrial
67. Miscellaneous CNS Pediatric
Cancer and Uterine Sarcoma
Tumors
50. Vulvar Cancer
68. Brain Metastases
51. Vaginal Cancer
69. Bone and Spine Metastasis
52. Adult Hodgkin's Lymphoma
70. Malignant Spinal Cord
53. Aggressive Non-Hodgkin's Compression
Lymphoma
71. Superior Vena Cava Syndrome
54. Indolent Non-Hodgkin's
72. Palliative Radiation Therapy
Lymphoma
73. Oligometastatic Disease
55. Multiple Myeloma and
Plasmacytoma 74. Radiation Therapy for Benign
Diseases
, 2
Chapter 1: Glioblastoma, IDH-Wildtype
Question 1. An exam-style case on glioblastoma, idh-wildtype asks for the initial
management priority. What is the best answer?
A. ignore concurrent chemoradiation when choosing dose, volumes, and
supportive care
B. use a broader but nonselective field arrangement that increases normal tissue
exposure
C. delay definitive decision-making despite actionable staging information
D. favor organ-preserving management when disease control remains
uncompromised
✅ Correct Answer: D. favor organ-preserving management when disease control
remains uncompromised
Rationale: In this presentation, favor organ-preserving management when disease
control remains uncompromised best addresses the dominant oncologic problem:
concurrent chemoradiation. Competing answers would be reasonable in different
settings, but not when this patient profile points most strongly toward the selected
approach.
DIF: Hard
TOP: Glioblastoma, IDH-Wildtype — fractionation / concurrent chemoradiation
MSC: NCLEX Client Needs Category: Safety and Infection Control
Question 2. For a patient with newly evaluated glioblastoma, idh-wildtype, which
option best reflects the best radiation technique selection?
A. obtain the imaging or pathologic clarification that changes treatment intensity
B. delay definitive decision-making despite actionable staging information
, 3
C. use a broader but nonselective field arrangement that increases normal tissue
exposure
D. ignore target delineation when choosing dose, volumes, and supportive care
✅ Correct Answer: A. obtain the imaging or pathologic clarification that changes
treatment intensity
Rationale: obtain the imaging or pathologic clarification that changes treatment
intensity is correct because it improves disease control while respecting the key
tradeoff of Glioblastoma, IDH-Wildtype: the need for strict image guidance and
motion management. The remaining options are less appropriate because they
either under-treat the likely extent of disease, ignore risk stratification, or increase
toxicity without a clear clinical gain.
DIF: Moderate
TOP: Glioblastoma, IDH-Wildtype — organs at risk / target delineation
MSC: NCLEX Client Needs Category: Safety and Infection Control
Question 3. When treating glioblastoma, idh-wildtype, which approach best
addresses the most relevant target volume consideration?
A. delay definitive decision-making despite actionable staging information
B. counsel the patient about expected acute toxicity and supportive measures
before treatment begins
C. ignore pseudoprogression when choosing dose, volumes, and supportive care
D. use a broader but nonselective field arrangement that increases normal tissue
exposure
✅ Correct Answer: B. counsel the patient about expected acute toxicity and
supportive measures before treatment begins
Rationale: For Glioblastoma, IDH-Wildtype, counsel the patient about expected
acute toxicity and supportive measures before treatment begins is preferred when
, 4
the goal is to optimize pseudoprogression without adding avoidable toxicity. Other
options are less suitable because they miss the dominant pattern of spread or fail to
address the most urgent therapeutic issue.
DIF: Easy
TOP: Glioblastoma, IDH-Wildtype — combined modality care /
pseudoprogression
MSC: NCLEX Client Needs Category: Safety and Infection Control
Question 4. A patient with glioblastoma, idh-wildtype is being discussed at tumor
board after standard staging. Which consideration is most important for the most
appropriate organ-at-risk consideration?
A. use a broader but nonselective field arrangement that increases normal tissue
exposure
B. ignore MGMT methylation when choosing dose, volumes, and supportive care
C. deliver guideline-concordant definitive radiation with appropriate staging and
immobilization
D. delay definitive decision-making despite actionable staging information
✅ Correct Answer: C. deliver guideline-concordant definitive radiation with
appropriate staging and immobilization
Rationale: Because MGMT methylation is central in Glioblastoma, IDH-Wildtype,
the safest next step is deliver guideline-concordant definitive radiation with
appropriate staging and immobilization. The distractors each overlook an essential
principle of management for this disease, such as appropriate staging, dose
selection, or organ preservation.
DIF: Easy
TOP: Glioblastoma, IDH-Wildtype — supportive care / MGMT methylation
MSC: NCLEX Client Needs Category: Safety and Infection Control
, 5
Question 5. During planning for glioblastoma, idh-wildtype, the team must decide
the finding that changes prognosis most strongly. Which choice is most appropriate?
A. ignore corticosteroid management when choosing dose, volumes, and
supportive care
B. use a broader but nonselective field arrangement that increases normal tissue
exposure
C. delay definitive decision-making despite actionable staging information
D. prioritize multidisciplinary evaluation before finalizing radiation volumes
✅ Correct Answer: D. prioritize multidisciplinary evaluation before finalizing
radiation volumes
Rationale: The option most aligned with contemporary management of
Glioblastoma, IDH-Wildtype is prioritize multidisciplinary evaluation before
finalizing radiation volumes, especially when subclinical spread patterns typical of
this disease site. The alternatives are weaker choices because they do not match the
timing, biology, or anatomic priorities in this case.
DIF: Moderate
TOP: Glioblastoma, IDH-Wildtype — recurrence management / corticosteroid
management
MSC: NCLEX Client Needs Category: Safety and Infection Control
Question 6. An exam-style case on glioblastoma, idh-wildtype asks for the
postoperative indication for adjuvant radiation. What is the best answer?
A. treat the gross disease and highest-risk microscopic extension while respecting
normal tissue constraints
B. delay definitive decision-making despite actionable staging information
C. use a broader but nonselective field arrangement that increases normal tissue
exposure
, 6
D. ignore maximal safe resection when choosing dose, volumes, and supportive
care
✅ Correct Answer: A. treat the gross disease and highest-risk microscopic
extension while respecting normal tissue constraints
Rationale: In this presentation, treat the gross disease and highest-risk microscopic
extension while respecting normal tissue constraints best addresses the dominant
oncologic problem: maximal safe resection. Competing answers would be
reasonable in different settings, but not when this patient profile points most
strongly toward the selected approach.
DIF: Hard
TOP: Glioblastoma, IDH-Wildtype — survivorship / maximal safe resection
MSC: NCLEX Client Needs Category: Safety and Infection Control
Question 7. For a patient with newly evaluated glioblastoma, idh-wildtype, which
option best reflects the best concurrent systemic therapy context?
A. delay definitive decision-making despite actionable staging information
B. expedite therapy because delay can worsen local control and functional outcome
C. ignore concurrent chemoradiation when choosing dose, volumes, and supportive
care
D. use a broader but nonselective field arrangement that increases normal tissue
exposure
✅ Correct Answer: B. expedite therapy because delay can worsen local control
and functional outcome
Rationale: expedite therapy because delay can worsen local control and functional
outcome is correct because it improves disease control while respecting the key
tradeoff of Glioblastoma, IDH-Wildtype: the need to synchronize local therapy
with chemotherapy or immunotherapy. The remaining options are less appropriate
, 2
Essentials of Clinical Radiation
Oncology –Test Bank
Third Edition
Chapter List
1. Glioblastoma, IDH-Wildtype 20. Cutaneous Squamous Cell
2. IDH-Mutant Gliomas: Grade 3 Carcinoma and Basal Cell Carcinoma
3. Low Grade Gliomas 21. Merkel Cell Carcinoma
4. Meningioma 22. Malignant Cutaneous Melanoma
5. Primary Central Nervous System 23. Mycosis Fungoides
Lymphoma 24. Early-Stage Breast Cancer
6. Pituitary Neuroendocrine Tumor 25. Locally Advanced Breast Cancer
7. Trigeminal Neuralgia 26. Ductal Carcinoma In Situ
8. Vestibular Schwannoma 27. Recurrent Breast Cancer
9. Uveal Melanoma 28. Early-Stage Non–Small-Cell Lung
10. Spine Tumors Cancer
11. Oropharynx Cancer 29. Stage III Non–Small-Cell Lung
Cancer
12. Oral Cavity Cancer
30. Small-Cell Lung Cancer
13. Nasopharyngeal Cancer
31. Mesothelioma
14. Laryngeal Cancer
32. Thymoma
15. Salivary Gland Tumors
33. Esophageal Cancer
16. Carcinoma of Unknown Primary of
the Head and Neck 34. Gastric Cancer
17. Postoperative Radiation for Head 35. Hepatocellular Carcinoma
and Neck Cancer 36. Pancreatic Adenocarcinoma
18. Thyroid Cancer 37. Rectal Cancer
19. Sinonasal Tumors 38. Anal Cancer
39. Cholangiocarcinoma
, 2
40. Low-Risk Prostate Cancer 56. Leukemia
41. Intermediate- and High-Risk 57. Soft Tissue Sarcoma
Prostate Cancer 58. Medulloblastoma
42. Post-Prostatectomy Radiation 59. Ependymoma
Therapy
60. Brainstem Glioma
43. Bladder Cancer
61. Craniopharyngioma
44. Testicular Cancer
62. Rhabdomyosarcoma
45. Penile Cancer
63. Neuroblastoma
46. Urethral Cancer
64. Wilms Tumor
47. Renal Cell Carcinoma
65. Ewing Sarcoma
48. Cervical Cancer
66. Pediatric Hodgkin Lymphoma
49. Uterine Cancer: Endometrial
67. Miscellaneous CNS Pediatric
Cancer and Uterine Sarcoma
Tumors
50. Vulvar Cancer
68. Brain Metastases
51. Vaginal Cancer
69. Bone and Spine Metastasis
52. Adult Hodgkin's Lymphoma
70. Malignant Spinal Cord
53. Aggressive Non-Hodgkin's Compression
Lymphoma
71. Superior Vena Cava Syndrome
54. Indolent Non-Hodgkin's
72. Palliative Radiation Therapy
Lymphoma
73. Oligometastatic Disease
55. Multiple Myeloma and
Plasmacytoma 74. Radiation Therapy for Benign
Diseases
, 2
Chapter 1: Glioblastoma, IDH-Wildtype
Question 1. An exam-style case on glioblastoma, idh-wildtype asks for the initial
management priority. What is the best answer?
A. ignore concurrent chemoradiation when choosing dose, volumes, and
supportive care
B. use a broader but nonselective field arrangement that increases normal tissue
exposure
C. delay definitive decision-making despite actionable staging information
D. favor organ-preserving management when disease control remains
uncompromised
✅ Correct Answer: D. favor organ-preserving management when disease control
remains uncompromised
Rationale: In this presentation, favor organ-preserving management when disease
control remains uncompromised best addresses the dominant oncologic problem:
concurrent chemoradiation. Competing answers would be reasonable in different
settings, but not when this patient profile points most strongly toward the selected
approach.
DIF: Hard
TOP: Glioblastoma, IDH-Wildtype — fractionation / concurrent chemoradiation
MSC: NCLEX Client Needs Category: Safety and Infection Control
Question 2. For a patient with newly evaluated glioblastoma, idh-wildtype, which
option best reflects the best radiation technique selection?
A. obtain the imaging or pathologic clarification that changes treatment intensity
B. delay definitive decision-making despite actionable staging information
, 3
C. use a broader but nonselective field arrangement that increases normal tissue
exposure
D. ignore target delineation when choosing dose, volumes, and supportive care
✅ Correct Answer: A. obtain the imaging or pathologic clarification that changes
treatment intensity
Rationale: obtain the imaging or pathologic clarification that changes treatment
intensity is correct because it improves disease control while respecting the key
tradeoff of Glioblastoma, IDH-Wildtype: the need for strict image guidance and
motion management. The remaining options are less appropriate because they
either under-treat the likely extent of disease, ignore risk stratification, or increase
toxicity without a clear clinical gain.
DIF: Moderate
TOP: Glioblastoma, IDH-Wildtype — organs at risk / target delineation
MSC: NCLEX Client Needs Category: Safety and Infection Control
Question 3. When treating glioblastoma, idh-wildtype, which approach best
addresses the most relevant target volume consideration?
A. delay definitive decision-making despite actionable staging information
B. counsel the patient about expected acute toxicity and supportive measures
before treatment begins
C. ignore pseudoprogression when choosing dose, volumes, and supportive care
D. use a broader but nonselective field arrangement that increases normal tissue
exposure
✅ Correct Answer: B. counsel the patient about expected acute toxicity and
supportive measures before treatment begins
Rationale: For Glioblastoma, IDH-Wildtype, counsel the patient about expected
acute toxicity and supportive measures before treatment begins is preferred when
, 4
the goal is to optimize pseudoprogression without adding avoidable toxicity. Other
options are less suitable because they miss the dominant pattern of spread or fail to
address the most urgent therapeutic issue.
DIF: Easy
TOP: Glioblastoma, IDH-Wildtype — combined modality care /
pseudoprogression
MSC: NCLEX Client Needs Category: Safety and Infection Control
Question 4. A patient with glioblastoma, idh-wildtype is being discussed at tumor
board after standard staging. Which consideration is most important for the most
appropriate organ-at-risk consideration?
A. use a broader but nonselective field arrangement that increases normal tissue
exposure
B. ignore MGMT methylation when choosing dose, volumes, and supportive care
C. deliver guideline-concordant definitive radiation with appropriate staging and
immobilization
D. delay definitive decision-making despite actionable staging information
✅ Correct Answer: C. deliver guideline-concordant definitive radiation with
appropriate staging and immobilization
Rationale: Because MGMT methylation is central in Glioblastoma, IDH-Wildtype,
the safest next step is deliver guideline-concordant definitive radiation with
appropriate staging and immobilization. The distractors each overlook an essential
principle of management for this disease, such as appropriate staging, dose
selection, or organ preservation.
DIF: Easy
TOP: Glioblastoma, IDH-Wildtype — supportive care / MGMT methylation
MSC: NCLEX Client Needs Category: Safety and Infection Control
, 5
Question 5. During planning for glioblastoma, idh-wildtype, the team must decide
the finding that changes prognosis most strongly. Which choice is most appropriate?
A. ignore corticosteroid management when choosing dose, volumes, and
supportive care
B. use a broader but nonselective field arrangement that increases normal tissue
exposure
C. delay definitive decision-making despite actionable staging information
D. prioritize multidisciplinary evaluation before finalizing radiation volumes
✅ Correct Answer: D. prioritize multidisciplinary evaluation before finalizing
radiation volumes
Rationale: The option most aligned with contemporary management of
Glioblastoma, IDH-Wildtype is prioritize multidisciplinary evaluation before
finalizing radiation volumes, especially when subclinical spread patterns typical of
this disease site. The alternatives are weaker choices because they do not match the
timing, biology, or anatomic priorities in this case.
DIF: Moderate
TOP: Glioblastoma, IDH-Wildtype — recurrence management / corticosteroid
management
MSC: NCLEX Client Needs Category: Safety and Infection Control
Question 6. An exam-style case on glioblastoma, idh-wildtype asks for the
postoperative indication for adjuvant radiation. What is the best answer?
A. treat the gross disease and highest-risk microscopic extension while respecting
normal tissue constraints
B. delay definitive decision-making despite actionable staging information
C. use a broader but nonselective field arrangement that increases normal tissue
exposure
, 6
D. ignore maximal safe resection when choosing dose, volumes, and supportive
care
✅ Correct Answer: A. treat the gross disease and highest-risk microscopic
extension while respecting normal tissue constraints
Rationale: In this presentation, treat the gross disease and highest-risk microscopic
extension while respecting normal tissue constraints best addresses the dominant
oncologic problem: maximal safe resection. Competing answers would be
reasonable in different settings, but not when this patient profile points most
strongly toward the selected approach.
DIF: Hard
TOP: Glioblastoma, IDH-Wildtype — survivorship / maximal safe resection
MSC: NCLEX Client Needs Category: Safety and Infection Control
Question 7. For a patient with newly evaluated glioblastoma, idh-wildtype, which
option best reflects the best concurrent systemic therapy context?
A. delay definitive decision-making despite actionable staging information
B. expedite therapy because delay can worsen local control and functional outcome
C. ignore concurrent chemoradiation when choosing dose, volumes, and supportive
care
D. use a broader but nonselective field arrangement that increases normal tissue
exposure
✅ Correct Answer: B. expedite therapy because delay can worsen local control
and functional outcome
Rationale: expedite therapy because delay can worsen local control and functional
outcome is correct because it improves disease control while respecting the key
tradeoff of Glioblastoma, IDH-Wildtype: the need to synchronize local therapy
with chemotherapy or immunotherapy. The remaining options are less appropriate
